Contact
searchSearch
HMP Global
Login

Non-Small Cell Lung Cancer Videos

Non-small cell lung cancer, NSCLC
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis: Part 2
06/19/2026
Rahul Mudumba, PhD, MHS
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how emerging real-world evidence may help differentiate ALK-targeted therapies for non–small cell lung cancer (NSCLC), highlighting the promise of lorlatinib, the importance of patient-specific treatment decisions,...
Dr Rahul Mudumba discusses how...
06/19/2026
Journal of Clinical Pathways
NSCLC, non-small cell lung cancer
Videos
Evaluating First-Line TKIs in ALK-Positive NSCLC: Insights From a Large Real-World Analysis
06/18/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how real-world evidence is helping clarify first-line treatment selection among ALK-targeted therapies in ALK-positive non–small cell lung cancer (NSCLC).
Rahul Mudumba, PhD, explains how...
06/18/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment: Part 2
03/24/2026
Rahul Mudumba, PhD, MHS
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how real-world evidence can refine value-based pathway decisions for ALK-positive non–small cell lung cancer (NSCLC) and previews new research on first-line ALK inhibitor effectiveness.
Rahul Mudumba discusses how...
03/24/2026
Journal of Clinical Pathways
NSCLC
Videos
Bridging Clinical Trials and Real-World Evidence in ALK-Positive Non–Small Cell Lung Cancer Treatment
03/24/2026
Rahul Mudumba, PhD, MHS
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba discusses findings from his study on real-world treatment patterns and time-to-treatment discontinuation among patients with advanced ALK-positive non–small cell lung cancer.
In this interview, Rahul Mudumba...
03/24/2026
Journal of Clinical Pathways
Corey Langer, MD, Abramson Cancer Center
Videos
Treatment Selection for ALK-Positive Metastatic Non-Small Cell Lung Cancer
09/04/2025
Corey J. Langer, MD, FACP
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a case demonstrating how liquid biopsy identified an ALK fusion and guided treatment with alectinib, resulting in durable disease control and preserved quality of life in an older patient with metastatic non-small...
Corey Langer, MD, presents a...
09/04/2025
Oncology
Chang Headshot
Videos
Optimizing Pathways in NSCLC With Immunotherapy and Radiation
11/22/2024
Joe Y. Chang, MD, PhD
Joe Y. Chang, MD, PhD, explores advancements in NSCLC treatment pathways, emphasizing the integration of immunotherapy and precision radiotherapy, the role of value-based care in palliative approaches, and the potential of artificial...
Joe Y. Chang, MD, PhD, explores advancements in NSCLC treatment pathways, emphasizing the integration of immunotherapy and precision radiotherapy, the role of value-based care in palliative approaches, and the potential of artificial...
Joe Y. Chang, MD, PhD, explores...
11/22/2024
Journal of Clinical Pathways
Sawsan Rashdan, MD
Videos
Future Directions in NSCLC Care: Navigating Pathways, Costs, and Cutting-Edge Therapies
11/14/2024
Sawsan Rashdan, MD
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate professor at UT Southwestern Medical Center specializing in lung cancer, discusses the transformative impact of targeted therapies and immunotherapies on NSCLC treatment.
Dr. Sawsan Rashdan, an associate...
11/14/2024
Journal of Clinical Pathways
Federico Cappuzzo, MD, National Cancer Institute Regina Elena
Videos
The Impact of Subcutaneous Formulation of Atezolizumab on Treatment for Patients with Non-Small Cell Lung Cancer
10/17/2024
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses the benefits of the subcutaneous formulation of atezolizumab compared with the intravenous route.
Federico Cappuzzo, MD, discusses...
10/17/2024
Oncology
Yating Wang, MD
Videos
Survival Trends Among Patients With Metastatic NSCLC Before and After the Approval of Immunotherapy in the US
09/27/2024
Yating Wang, MD
Yating Wang, MD, shares the findings and future implications of her study on survival trends among patients with metastatic non–small cell lung cancer (NSCLC) before and after the approval of immunotherapy in the US.
Yating Wang, MD, shares the findings and future implications of her study on survival trends among patients with metastatic non–small cell lung cancer (NSCLC) before and after the approval of immunotherapy in the US.
Yating Wang, MD, shares the...
09/27/2024
Journal of Clinical Pathways
Alexander Spira, MD, PhD
Videos
Unmet Needs in the Treatment and Management of Non–Small Cell Lung Cancer
09/26/2024
Alexander Spira, MD, PhD
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD, discusses significant unmet needs in the treatment and management of non–small cell lung cancer (NSCLC).
Alexander I. Spira, MD, PhD,...
09/26/2024
Journal of Clinical Pathways

Special Reports

Special Report
Advancing a Standardized Economic Framework to Power Oncology Pathways: Methods and Model Development From Phase II of the Predictable Cost of Care Working Group
04/23/2026
Edward Arrowsmith, MD; Alan J. Balch, PhD, MSc; Vishnukamal Golla, MD, MPH; Andrew Hertler, MD, FACP; David Jackman, MD; Olaf Lodbrok, MS, MBA; Lalan Wilfong, MD; Gordon Kuntz; Carole Tremonti, RN, MBA
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and costs rise, oncology pathway developers need consistent, transparent methods to compare treatment options beyond drug acquisition costs. Building on Phase I’s consensus on relevant cost domains, the Phase II PCC...
As cancer therapies expand and...
04/23/2026
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use